PremiumRatingsCautious Outlook on Agilon Health: Financial Challenges and Strategic Concerns Drive Sell Rating Agilon Health Reports Q1 2025 Financial Results Agilon Health: Hold Rating Amid Positive Results and Cost Concerns PremiumThe FlyAgilon Health options imply 12.8% move in share price post-earnings AGL Earnings this Week: How Will it Perform? Agilon Health upgraded to Buy from Neutral at Citi PremiumThe FlyAgilon Health price target raised to $6 from $3.50 at TD Cowen Balanced Outlook on Agilon Health: Hold Rating Amid Cautious Profitability and Conservative Revenue Growth Agilon Health price target lowered to $5 from $6 at Baird 
